Showing 651 results
- Media Release /- Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation- Approval based on…
- Media Release /
- Media Release /-- Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate1-- Patients with NTDT accumulate…
- Media Release /
- Media Release /- Endpoints met in two Phase III trials, including substantial symptom relief in 84% of systemic juvenile idiopathic arthritis (SJIA) patients treated with ACZ885 in trial-11- SJIA patients treated…
- Media Release /
- Media Release /- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
- Media Release /
- Media Release /- As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease(1)- In the Phase III trial, most patients…
- Media Release /
Pagination
- ‹ Previous page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- …
- 66
- › Next page